The global Fusidic Acid market remained stable in June 2025, supported by balanced supply availability, consistent pharmaceutical demand, and strategic pricing from suppliers. India’s API overcapacity, driven by increased domestic production and lower raw material costs, influenced global market sentiment, maintaining overall steadiness. Pharmaceutical and dermatology sectors sustained routine procurement aligned with production cycles, preventing major fluctuations. Anticipation of seasonal demand and efficient inventory management further contributed to market equilibrium, with only marginal regional variations expected in the near term.
